{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-065618","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.118915+00:00","generated_at":"2026-05-22T08:14:39.863169+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Revolution Medicines Q1 net loss $213.4M; highlights encouraging RAS inhibitor data","bullets":["Net loss $213.4M (vs $116.0M YoY); R&D $205.7M, G&A $35.0M; cash $2.1B.","FY 2025 GAAP net loss guidance reaffirmed $840M-$900M; cash runway into H2 2027.","Daraxonrasib Phase 3 PDAC trial enrollment to substantially complete in 2025; data in 2026.","Zoldonrasib G12D NSCLC ORR 61%; elironrasib G12C NSCLC ORR 56%, median PFS 9.9 mo.","Anthony Mancini named chief global commercialization officer."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-065618","json":"https://secwatch.observer/filing/0000950170-25-065618.json","markdown":"https://secwatch.observer/filing/0000950170-25-065618.md","text":"https://secwatch.observer/filing/0000950170-25-065618.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000095017025065618/0000950170-25-065618-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000095017025065618/rvmd-20250507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T08:14:39.863169+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}